Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice.

Kim,  Nam Hoon; Kim,  Sin Gon

doi:2017.18.3.135

J Korean Diabetes > Volume 18(3); 2017 > Article

Opinion

The Journal of Korean Diabetes 2017;18(3):135-140.
DOI: https://doi.org/10.4093/jkd.2017.18.3.135 Published online October 12, 2017.

Dipeptidyl Peptidase-4 억제제와 Sodium Glucose Cotransporter 2 억제제의 새로운 안전성 이슈: 어떻게 해석하고 진료현장에 적용할 것인가?

김남훈, 김신곤

Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice.

Nam Hoon Kim, Sin Gon Kim

Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. k50367@korea.ac.kr

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose co-transporter 2 (SGLT2) inhibitors are newer classes of glucose-lowering agents that are currently widely used in clinical practice. Their glycemic efficacy and cardiovascular safety have been well proven, and recent large clinical trials even have shown cardiovascular benefits of SGLT2 inhibitors. However, data regarding drug-related long-term safety remain inconclusive. Recently, several safety issues related to DPP-4 inhibitors and SGLT2 inhibitors have been raised by cardiovascular outcome trials or post-marketing pharmacoepidemiological studies. In this review, we summarize emerging safety issues regarding the use of DPP-4 inhibitors and SGLT2 inhibitors in type 2 diabetes and suggest how to interpret and apply these results to clinical practice.

Key Words: Diabetes mellitus, type 2, Dipeptidyl-peptidase IV inhibitors, Safety, Sodium glucose cotransporter 2 inhibitor